Advanced Prostate Cancer

/Advanced Prostate Cancer

SpaceOar Hydrogel to Protect Your Rectum During Radiation Therapy

Radiation therapy might hurt men by inadvertently damaging their rectum. Men considering radiation therapy would be wise to ask their radiation oncologist about SpaceOar, a hydrogel product. SpaceOAR stands for Spacing Organs at Risk. Think of SpaceOar as a rectal spacer.  Hydrogel is a water-like substance that’s injected between the rectum and prostate in order [...]

By |2018-09-18T15:27:32+00:00September 18th, 2018|Advanced Prostate Cancer|0 Comments

Treating prostate cancer with antidepressants

Treating prostate cancer with antidepressants Imagine treating Prostate Cancer with an anti-depressant medication. A new USC School of Pharmacy study suggests that the monoamine oxidase-A enzyme (MAO-A) pathway could be used for treating prostate cancer. The drugs under consideration are the new, third generation of reversible, selective MAO-A inhibitors such as moclobemide, toloxatone and brofaromine, [...]

By |2018-08-02T16:07:22+00:00August 2nd, 2018|Advanced Prostate Cancer, General Information|0 Comments

How Does Radiation Therapy Cure Prostate Cancer?

Radiation is high energy x-rays. When you are depositing energy into a target with the latest technology, you're able to kill off a tumor and you're able to preferentially address a given region and to spare the adjacent tissues around that region. There are different types of radiation, but therapeutic radiation is high dose [...]

By |2018-07-23T17:00:01+00:00July 23rd, 2018|Advanced Prostate Cancer, General Information|0 Comments

Is Cyberknife a good prostate cancer treatment?

https://youtu.be/JnnE7X4tRZc Precision Radiation Treatment . Cyberknife has improved prostate cancer treatment as dynamically as robotic surgery . But, Cyberknife is not for everyone. See if it's right for you. Seth Blacksburg, MD and Darryl Mitteldorf, LCSW, explain. 1. How does radiation therapy actually work? 00:44 2. Does radiation therapy cause second cancers? 06:28 3. [...]

By |2018-07-18T12:43:54+00:00July 18th, 2018|Advanced Prostate Cancer|0 Comments

Emotional Crisis Resources From Malecare

Malecare's collection of emotion crisis resources.  Call these, even if you don't know if you "really" need them. Many international calls are free or affordable with SKYPE and many other apps. Feel OK about calling resources outside of your country. US: Hopeline (Suicide Prevention): 1-800-SUICIDE (1-800-784-2433) US: Suicide Hotline: 1-800-273-Talk (1-800-8255) UK: Samaritans (Nat’l [...]

By |2018-06-08T09:07:40+00:00June 8th, 2018|Advanced Prostate Cancer|0 Comments

Prostate Cancer And Agent Orange Is Not The Only Military Concern

Agent Orange is usually the first thing veterans with prostate cancer ask about.   Indeed, way back in 1998, Malecare was an early advocate for men exposed to Agent Orange. Military veterans as well as Vietnamese, Cambodian and Laotian civilians were exposed to Agent Orange, and many of those who are men are now diagnosed, [...]

By |2018-05-27T23:55:25+00:00May 25th, 2018|Advanced Prostate Cancer, Advocacy, Research|3 Comments

Erleada- New Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Erleada (apalutamide) has just received FDA approval as a drug for treating men with non-metastatic castration-resistant prostate cancer.   The proper pronunciation is Er ( Errr), (Like Her without the h) ) (lee) (long E) da. Now, repeat after me, "Erleada!" It's a pill that you take - I believe - four times a [...]

Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)  usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]

XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces developing metastases or death

Non-metastatic Castrate Resistant prostate cancer patients take note.  The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone.  It will be a [...]